STERIS plc (STE) stock
STENYSEOrthopedic, Prosthetic & Surgical Appliances & SuppliesFiscal year ends March 31
Financials through Q2 FY2027, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 21/303% below fair value
$253.44−2.83 (-1.10%)
Close on Nov 12, 2026Market cap $24.71BP/E 30.1Yield 0.97%
Steris r&d expenses
Research and development expenses are spending on new products and technology.
Steris's R&D Expenses for the twelve months ending Sep 30, 2026 was $118.40M, up 8.0% year over year. For fiscal 2026 it was $112.90M, up 4.9% from the year before. The highest annual figure on record is $112.90M in fiscal 2026.
Annual r&d expenses
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2026 | Mar 31, 2026 | $112.90M | +4.9% |
| FY2025 | Mar 31, 2025 | $107.60M | +3.8% |
| FY2024 | Mar 31, 2024 | $103.70M | +5.3% |
| FY2023 | Mar 31, 2023 | $98.48M | +13.6% |
| FY2022 | Mar 31, 2022 | $86.66M | +30.7% |
| FY2021 | Mar 31, 2021 | $66.33M | +1.2% |
| FY2020 | Mar 31, 2020 | $65.55M | +4.0% |
| FY2019 | Mar 31, 2019 | $63.04M | +3.7% |
| FY2018 | Mar 31, 2018 | $60.78M | +2.3% |
| FY2017 | Mar 31, 2017 | $59.40M | – |
Quarterly r&d expenses
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2027CQ3 2026 | Sep 30, 2026 | $31.50M | +11.7% |
| Q1 FY2027CQ2 2026 | Jun 30, 2026 | $28.60M | +8.3% |
| Q4 FY2026CQ1 2026 | Mar 31, 2026 | $28.80M | +4.3% |
| Q3 FY2026CQ4 2025 | Dec 31, 2025 | $29.50M | +7.7% |
| Q2 FY2026CQ3 2025 | Sep 30, 2025 | $28.20M | +4.4% |
| Q1 FY2026CQ2 2025 | Jun 30, 2025 | $26.40M | +3.1% |
| Q4 FY2025CQ1 2025 | Mar 31, 2025 | $27.60M | +0.4% |
| Q3 FY2025CQ4 2024 | Dec 31, 2024 | $27.40M | +8.5% |
| Q2 FY2025CQ3 2024 | Sep 30, 2024 | $27.00M | +2.8% |
| Q1 FY2025CQ2 2024 | Jun 30, 2024 | $25.60M | +3.7% |
| Q4 FY2024CQ1 2024 | Mar 31, 2024 | $27.48M | +18.0% |
| Q3 FY2024CQ4 2023 | Dec 31, 2023 | $25.26M | -1.0% |
| Q2 FY2024CQ3 2023 | Sep 30, 2023 | $26.27M | +5.4% |
| Q1 FY2024CQ2 2023 | Jun 30, 2023 | $24.69M | -0.2% |
| Q4 FY2023CQ1 2023 | Mar 31, 2023 | $23.28M | -6.2% |
| Q3 FY2023CQ4 2022 | Dec 31, 2022 | $25.51M | +2.8% |
| Q2 FY2023CQ3 2022 | Sep 30, 2022 | $24.93M | +32.4% |
| Q1 FY2023CQ2 2022 | Jun 30, 2022 | $24.75M | +36.1% |
| Q4 FY2022CQ1 2022 | Mar 31, 2022 | $24.82M | +41.7% |
| Q3 FY2022CQ4 2021 | Dec 31, 2021 | $24.82M | +51.0% |
| Q2 FY2022CQ3 2021 | Sep 30, 2021 | $18.83M | +16.7% |
| Q1 FY2022CQ2 2021 | Jun 30, 2021 | $18.19M | +12.1% |
| Q4 FY2021CQ1 2021 | Mar 31, 2021 | $17.51M | +1.7% |
| Q3 FY2021CQ4 2020 | Dec 31, 2020 | $16.44M | -0.3% |
| Q2 FY2021CQ3 2020 | Sep 30, 2020 | $16.14M | -0.7% |
| Q1 FY2021CQ2 2020 | Jun 30, 2020 | $16.23M | +4.1% |
| Q4 FY2020CQ1 2020 | Mar 31, 2020 | $17.23M | +8.5% |
| Q3 FY2020CQ4 2019 | Dec 31, 2019 | $16.49M | +8.7% |
| Q2 FY2020CQ3 2019 | Sep 30, 2019 | $16.25M | +3.0% |
| Q1 FY2020CQ2 2019 | Jun 30, 2019 | $15.59M | -3.9% |
| Q4 FY2019CQ1 2019 | Mar 31, 2019 | $15.88M | – |
| Q3 FY2019CQ4 2018 | Dec 31, 2018 | $15.17M | – |
| Q2 FY2019CQ3 2018 | Sep 30, 2018 | $15.77M | – |
| Q1 FY2019CQ2 2018 | Jun 30, 2018 | $16.22M | – |
See a number that looks wrong?